Vendor dossier · Shenzhen, Guangdong
Shenzhen Hybio Pharmaceutical Co., Ltd.
A Shenzhen peptide house that has made active ingredient to contract since 2003, and releases its research catalogue against the same quality system.
Journal grade · ranked 5 of 21
962 reader reports
on the record
HYB is one of the few companies in this directory whose research catalogue is a secondary business rather than the whole of it. The Shenzhen entity and its 2003 incorporation are on the register, the company manufactures peptide active ingredient to contract for customers who audit it, and the 350-odd research compounds it lists are released against the documentation that work is released against. That is an unusual position in this trade and it is visible in the paperwork before it is visible anywhere else.
Storefront The company sells directly at hybiopharmaceutical.com. Visit HYB → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Nine independent purity determinations, mean 98.1%, range 97.3 to 98.9%, every result at or above the figure printed on the accompanying certificate. Method reference, gradient, column identifier, detection wavelength and integration threshold are present on all nine documents as standard rather than on request, which puts this file in the small group where nothing had to be asked for twice. It is also the only file in this programme where the gradient and the threshold were both on the page before anybody from this desk had written to ask for either.
The manufacturing claim is the part of the file that took longest to settle, because a company can describe itself as a manufacturer without ever having made anything. HYB answered directly. It named the Shenzhen site, stated which catalogue lines are synthesised there and which are finished there from material made elsewhere within its own group, and marked that distinction on the quotation from the second order onward without being asked again. The Journal has not conducted a site visit and does not claim to have verified the plant; what it has is a company that draws the distinction unprompted, which is not what a firm with something to lose by drawing it would do.
Fulfilment is unremarkable in the sense the word ought to have. Nine orders, nine deliveries, median transit ten days against a quoted seven to fourteen, certificates attached to the dispatch email rather than sent after the parcel, and one replacement issued on a photograph of a cracked flange without the request being made twice. Material has been submitted to all four of the services this desk uses, and the four have agreed with one another and with the certificate on every occasion.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Nine independent purity determinations, mean 98.1% (range 97.3 to 98.9%), every one at or above the figure on the accompanying certificate.
- Method, gradient, column, wavelength and integration threshold present on 9 of 9 certificates without a supplementary request.
- 2003 incorporation in Shenzhen consistent with registry records; the trading name on the invoice matches the name on the certificate on 9 of 9 orders.
- Synthesised lines and finished-from-sourced lines distinguished on the quotation before the order is taken.
Ordering: lead times, minimums and what to ask for
- Lead time: catalogue lines dispatch within two working days of cleared payment; median door-to-door transit ten days to a European address against a quoted seven to fourteen.
- Minimum quantity: single vials on the research catalogue; gram-scale minimums on active-ingredient enquiries, quoted in writing against a written schedule before order.
- Regional stock: the incretin and repair-peptide lines are held in finished vials; the longer sequences in the 350-plus catalogue are campaign-made on a four to six week cycle and quoted with the lead time attached.
- The certificate carries method reference, gradient, column, wavelength, integration threshold, batch and specification, with release signed and dated by a named individual. Ask for the batch record by quoting the batch number and the certificate reference together in the subject line; it has been supplied on both occasions we asked.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-04 | Medutest | Tesamorelin 2 mg | 97.5% | 97.9% | 99% |
| 2025-12 | Janoshik | Tirzepatide 10 mg | 97.6% | 97.8% | not tested |
| 2025-10 | Janoshik | Tirzepatide 10 mg | 97.2% | 97.3% | 99% |
| 2025-07 | VendorInvestigate | Tirzepatide 5 mg | 97.7% | 98.2% | not tested |
| 2025-04 | Medutest | Semaglutide 5 mg | 97.8% | 98.6% | 98% |
| 2025-01 | Medutest | Semaglutide 15 mg | 97.0% | 97.3% | 98% |
| 2024-10 | PeptideMeter | Tirzepatide 20 mg | 98.1% | 98.5% | 98% |
| 2024-06 | PeptideMeter | Cagrilintide 5 mg | 98.3% | 98.9% | not tested |
| 2024-02 | Medutest | Semaglutide 5 mg | 98.0% | 98.4% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 7 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-05 | Requested the reference-standard lot number behind a purity figure | Answered in full; the reference-standard lot was quoted and matched the supplier of the standard |
| 2025-12 | Asked for the name and location of the synthesis facility | Answered in full; the manufacturing site was named and the fill site named separately |
| 2025-06 | Asked how long finished stock is held before dispatch | Answered in full within 3 working days; holding period given per line, with the storage condition |
| 2025-04 | Asked whether release testing is performed per lot or per campaign | Answered in full; release is per lot, confirmed in writing and now printed on the certificate |
| 2024-11 | Asked which catalogue items are synthesised in-house | Answered in full within 2 working days; the in-house list was itemised |
| 2024-08 | Asked whether sterility or endotoxin testing is performed | Answered in full; endotoxin testing is available as an add-on and was quoted per lot |
| 2024-04 | Requested the counter-ion form and residual solvent data | Answered in full within 4 working days; counter-ion and residual solvents both supplied as figures |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
The certificate arrived with the integration threshold printed on it, which is the particular that decides whether a purity figure means anything at all. Peptide content was reported separately at 97.9%, permitting a direct conversion to working mass. I have no relationship with this supplier beyond having paid them.
I submitted a vial of tirzepatide 10 mg to Janoshik without disclosing its origin, and a second vial from the same lot to Medutest. The two figures agreed to within a tenth of a point and both sat above the certificate. Readers should test their own material regardless of anyone else's figures, including mine.
What decided me on this supplier was the answer to a question about the counter-ion. I was told the acid used in the final purification, the approximate mass fraction it accounts for, and what that means for the powder I weigh out. That is a manufacturer's answer rather than a reseller's.
Lot HYB-26-118 was released with the method, the gradient table and the column identifier on the page. I repeated the determination independently and landed at 98.4% against a stated 97.8%. Nothing here constitutes medical advice and I am not qualified to offer any.
Eleven orders across fourteen months and the striking thing is how little there is to write down. Dispatch inside two working days each time, documents attached to the dispatch email each time, and no line that proved unavailable after payment had cleared. Consistency rather than brilliance, and consistency is what I was buying.
The reconstitution behaviour of the semaglutide 5 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. A single purchaser is not a dataset and I do not present myself as one.
I asked whether a particular catalogue line was synthesised at the Shenzhen site or finished there from sourced material, expecting the question to be deflected. It was answered in one sentence, and the same distinction appeared on the quotation for the next order without my asking again. These compounds are for research use and are not approved for administration to humans.
The cold pack was still hard when the outer carton was opened on day nine, and the temperature indicator on the carton was unbreached. Cold chain is the limb of this trade most often described and least often evidenced. I offer this as one reader's record and not as a general finding.
I weighed nine vials from a cagrilintide 10 mg order against their stated fill. Every one fell inside two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline of the two.
A qualified five rather than a flat one: the first quotation came back priced per vial where I had asked for it priced per gram of peptide. Corrected inside a single reply, the price held, and the certificate that followed carried both figures. The material returned 98.2% independently. I record no complaint worth the Journal's column inches.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic for the sequence length, and the material was delivered four days inside it at the purity written into the signed schedule. That is the behaviour of a house that knows what its own reactors can do.
The batch record was supplied when I quoted the batch number and the certificate reference together in the subject line. I did not expect to receive it and I have not received it from most of the suppliers I have asked. Readers should test their own material regardless of anyone else's figures, including mine.
Water content is reported as standard here rather than on request. Between water and counter-ion sits most of the gap between fill mass and peptide mass, and a supplier that closes one of the two without being pressed has told you something about its quality system.
I reordered the same line at sixteen months specifically to look for process drift. The independent figure was 98.0% against 98.1% originally, on a certificate carrying the same method reference. Should the next lot hold, I shall stop testing every one. That is intended as praise.
The lot code on the vial, on the certificate and on the invoice were identical across four consignments. It is a low bar and it remains the most reliable single predictor of everything above it.
A technical query sent on a Friday evening was answered on the Monday with a figure and a unit rather than an assurance about quality, and the reply did not arrive attached to a sales approach. Nothing here constitutes medical advice and I am not qualified to offer any.
Stock availability as displayed proved accurate on all six occasions I have tested it, the order shipped the same day on four of them, and the material was in my hands inside a fortnight every time. I have no relationship with this supplier beyond having paid them.
I deduct nothing of substance, but readers should know that the first parcel was routed through a hub that added three days to the transit. The supplier told me it had happened before I noticed, which is the sequence that matters, and the phase-change pack was still hard on arrival. The independent determination came back at 97.6%.
Purity is reported by a stability-indicating method, the method is named, the wavelength is stated and the threshold is printed. A figure offered without those particulars is not a figure, and I have stopped paying for suppliers who offer one.
My first order here was deliberately modest, being a single vial of BPC-157 5 mg. Documentation, transit and an independent result at 98.6% were all satisfactory, and subsequent orders have not been modest. I shall continue to buy here, which is the only assessment that costs the writer anything.
Release on the certificate is signed and dated by a named individual with a job title beside the name. Readers who have spent any time comparing certificates will recognise how unusual that is in this trade.
Customs documentation was correct on first presentation on all five consignments, which is the actual explanation for a transit time that would otherwise look implausible. A single purchaser is not a dataset and I do not present myself as one.
A second certificate was requested for a lot bought eleven months previously. It was retrieved from their records and sent the same day, unedited, with the original determination date on it. Retention of records is not a feature anybody advertises and it is worth more than most of the features they do.
The observed and the calculated monoisotopic masses were both printed on the identity report, and they agreed. A mass measurement is not a sequence confirmation and the company does not pretend it is, which is itself a point in its favour. These compounds are for research use and are not approved for administration to humans.
One vial in a ten-vial consignment arrived with a hairline crack in the flange. I sent a photograph, the replacement shipped the next working day without argument or a restocking charge, and the remaining nine returned 98.3% on an independent determination. I offer this as one reader's record and not as a general finding.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct on first issue, and the material was what it was said to be. The documentation is as much the product as the powder.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from hybiopharmaceutical.com. Visit HYB → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Shenzhen Hybio Pharmaceutical Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.